EP0671916A1 - Systeme d'administration transdermique contenant de l'acide acetylsalicylique pour la therapie antithrombotique et la prophylaxie contre le cancer - Google Patents

Systeme d'administration transdermique contenant de l'acide acetylsalicylique pour la therapie antithrombotique et la prophylaxie contre le cancer

Info

Publication number
EP0671916A1
EP0671916A1 EP94900819A EP94900819A EP0671916A1 EP 0671916 A1 EP0671916 A1 EP 0671916A1 EP 94900819 A EP94900819 A EP 94900819A EP 94900819 A EP94900819 A EP 94900819A EP 0671916 A1 EP0671916 A1 EP 0671916A1
Authority
EP
European Patent Office
Prior art keywords
acetylsalicylic acid
administration system
transdermal administration
asa
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP94900819A
Other languages
German (de)
English (en)
Inventor
Frank Becher
Thomas Kissel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4241128A external-priority patent/DE4241128C2/de
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Priority claimed from PCT/EP1993/003231 external-priority patent/WO1994013302A1/fr
Publication of EP0671916A1 publication Critical patent/EP0671916A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Definitions

  • ASA acetylsalicylic acid
  • antithrombotic therapy is used in the following, these indications are essentially included.
  • acetylsalicylic acid is often used as a non-steroidal anti-inflammatory, analgesic and antipyretic agent.
  • ASA affects platelet function and prevents thrombosis by irreversibly inhibiting thromboxane A2 synthesis (M. Buchanan et al., "Aspirin inhibits platelet function independent of cyclooxygenase", Thrombosis Res. 25, 363-373 (1982)).
  • ASA is quickly absorbed after oral administration.
  • the biological half-life in the body circulation is very short, it only lasts 15-20 minutes (M.
  • Acetylsalicylic acid is continuously ingested by large sections of the population, particularly in the USA. According to a work by Thun et al., "Aspirin Use and Reduced Risk of Fatal Colon Cancer", New Engl. J. Med..225. 1593-1596 (1991), ASA reduced the mortality caused by colon cancer to about half when ASA was taken continuously, at least 16 days a month. The investigation included more than 660,000 people who had taken ASA for at least one year and lived in all 50 states in the United States, the Columbia District, and Puerto Rico. Although reference was only made to the use of ASA without further details regarding the mode of administration and the dose, it can nevertheless be assumed that the ASA had been taken orally and that the substance responsible for the action is not the hydrolysis product salicylic acid, but ASA itself.
  • ASS is mentioned in US Pat. No. 3,598,122 as a possible antipyretic active substance in a membrane-controlled transdermal therapeutic system.
  • FR-M 1757 describes the dermal topical application of an oil-in-water emulsion which contains 5% ASA for acute pain.
  • FR-A 2 297 612 claims rubbing agents and ointments which contain ASA as an analgesic agent.
  • ASS is used in US Pat. No. 4,012,508 for topical use in dermatological indications. US Pat. No.
  • ASS-containing gel is applied topically in EP-A 0055635 for anti-inflammatory, analgesic and antipyretic indications.
  • a device for the transdermal application of ASA from an aqueous system to achieve anti-inflammatory and analgesic effects is the subject of US Pat. No. 4,460,368.
  • ASS is applied topically from ethanolic solution in US Pat. No. 4,665,063 against dermatological disorders.
  • An increase in the penetration rate of ASA in the case of transdermal application is achieved in US Pat. No. 4,640,689 with electric current.
  • JP-OS 61 167 615 ASS is applied to the skin with the aid of a film.
  • US Pat. No. 4,810,699 describes combinations of ASA with other active substances for the transdermal treatment of inflammation, pain and fever.
  • Special penetration accelerators for the transdermal application of ASA as a pain reliever are contained in JP-PS 1 203 336.
  • Further substances of this type for ASA in transdermal application for inhibiting inflammation can be found in JP-PS 1, 242,521.
  • Storage-stable solutions from ASS for topical application with the aim of reducing inflammation and relieving pain are the subject of US Pat. No. 4,975,269.
  • transdermal system is used for the administration of acetylsalicylic acid and / or its pharmaceutically acceptable salts for antithrombotic therapy and / or for prophylaxis against cancer, preferably one which contains acetylsalicylic acid or the salts contains in a matrix that substantially suppresses or does not permit the hydrolysis of acetylsalicylic acid.
  • the system is preferably free of substances which, under the storage conditions or during use, cause the acetyl group to be split off.
  • a transdermal delivery system offers the following advantages in anti-thrombotic therapy:
  • ASA in its pharmacologically active form, is given directly to the body's circulation, thereby avoiding metabolism in the gastrointestinal tract.
  • the ASA content in such an administration unit is generally 5 to 500, preferably 30 to 200 mg or the corresponding amount of a pharmaceutically acceptable salt.
  • the ASS salts that can be used here are all non-toxic, pharmacologically active salts such as the lithium, sodium, potassium, magnesium and calcium salts or salts of ASS with basic organic compounds such as lysine, arginine or cetrimonium bromide (hexadecyltrimethylam onium bromide).
  • the rate and extent of the transdermal transfer of ASA into the body naturally depends on the amount, the type of compound (free acid or salt) and, if appropriate, also on the presence of auxiliaries such as penetration accelerators.
  • the system is expediently adjusted in such a way that an ASA blood level value between 0.1 and 1.0 ⁇ g / ml is established.
  • the content is expediently based on the type of matrix, the recommended wearing time of the F-Tlaster, the intended indication, the body weight (children or adults), the permeability of the matrix or membrane of the patch and the permeation through the skin Voted.
  • ASA blood level values between 0.1 and 1.0 ⁇ g / ml.
  • ASA is rapidly absorbed after oral administration, this type of administration is unfavorable, especially because of the hydrolysis of ASA to salicylic acid if the short biological half-life and the fact that the most constant possible administration is desirable for prophylaxis.
  • the transdermal treatment proposed according to the invention gives fairly constant and reproducible ASA blood level values which are particularly effective in anthrhrombotic therapy and are suitable for cancer prophylaxis.
  • a transdermal delivery system according to the invention ensures constant and reproducible ASA blood levels which are effective in antithrombotic therapy.
  • cancer prophylaxis e.g. understood one against cancer with tumor formation, e.g. in the gastrointestinal tract, such as colon cancer.
  • the transdermal administration system for ASA and / or ASA salts according to the invention can be implemented in a variety of ways, e.g. as a particularly pressure-sensitive adhesive plaster, as a film, as a spray, cream, ointment and the like.
  • Preferred is the form of administration of the pressure-sensitive adhesive plaster, which has an impermeable backing layer, an associated active substance reservoir made of a polymer matrix, in the absence of other control mechanisms, a membrane that controls the release of the active substance, a pressure-sensitive adhesive device for attaching the system to the skin and, if necessary includes a protective layer that can be removed before the system is applied.
  • care must be taken that the matrix forming the active substance reservoir is selected in such a way that the hydrolysis of ASA is avoided or at least strongly suppressed.
  • a hydrophobic setting of the matrix leads to the goal here rather than a hydrophilic one.
  • acylating agents preferably acetylating agents, in particular acetic anhydride, e.g. in an amount of 0.01 to 3, preferably 0.1 to 2 wt .-%, based on acetylsalicylic acid.
  • transdermal pressure-sensitive adhesive plasters which can be used according to the invention are all plasters which are known to the person skilled in the art from the prior art. They can largely be assigned to two basic control principles: matrix diffusion control and membrane control, only the latter having a zero-order release of active ingredient.
  • An F-raster with matrix diffusion control is described for example in DE-PS 33 15 272. It consists of an impermeable backing layer, an associated reservoir made of a polymer matrix, which contains the active ingredient in a concentration above the juicing concentration, a pressure-sensitive adhesive layer connected to the reservoir, permeable to the active ingredient, and a protective layer covering the adhesive layer, which can be removed again for use, e.g. a siliconized film made of polyester, especially polyethylene terephthalate. If the reservoir matrix itself is already pressure sensitive, you can use the additional adhesive layer can be dispensed with. However, systems with lower than the saturation concentration are also possible.
  • plasters with membrane control reference is made, for example, to US Pat. Nos. 3,742,951, 3,797,494, 3,996,934 and 4,031, 894.
  • These plasters basically consist of a backing layer (e.g. a film made of a polyester such as polyethylene terephthalate, which can be aluminized, or an aluminized film made of a synthetic resin such as polypropylene, nylon, polycaprolactam), which is one of the surfaces, a membrane, one for the Active substance permeable adhesive layer that represents the other surface and ultimately a reservoir that contains the active substance between the two layers forming the surfaces.
  • the active ingredient can also be contained in a large number of microcapsules which are distributed within the permeable adhesive layer.
  • the active ingredient is continuously released from the reservoir or the microcapsules through a membrane into the adhesive layer which is permeable to the active ingredient and which is in contact with the skin of the person to be treated.
  • the capsule material can also act as a membrane. Substances suitable for membranes and microcapsules are e.g. in U.S. Patent 3,996,934.
  • the plasters can contain various additives in addition to the matrix forming the reservoir and the active ingredient, which also includes combinations of ASA and their salts, in order to obtain the desired property profile.
  • Additives that promote the permeation of ASA and / or their pharmaceutically acceptable salts through the skin should be particularly mentioned.
  • a precise list of the additives is unnecessary for the person skilled in the art in this field, but mention may be made, for example, of glycerol, 1, 2-propanediol, the monomethyl or monoethyl ether of ethylene glycol, 2-octyldodecanol, the laurate, palmitate, stearate or oleate of sorbitol, C 8 -
  • the amount is generally from 0 to 20, preferably from 0.5 to 10,% by weight. %, based on the total components of the matrix. It depends on the type of matrix, the permeability of the matrix or membrane of the patch, the dissolving power of the penetration accelerator for the active ingredient and the permeation through the skin.
  • the invention is illustrated by the following examples:
  • the solution is then spread 300 ⁇ m thick on a siliconized, 100 ⁇ m thick polyester film. In the finished system, this film takes over the function of the removable protective layer and must be removed before use.
  • the moist film is dried at 50 ° C. for 20 minutes and then has a weight per unit area of 100 g / m 2 .
  • the dried film is then laminated with a 12 ⁇ m thick polyester film.
  • the finished plasters are punched out of the laminate.
  • the finished system consists of a removable protective layer, a skin adhesive layer, a non-adhesive reservoir, an active substance-impermeable back layer and a well-adhesive primer layer which is located between the reservoir layer and the back layer and has the task of anchoring the non-adhesive reservoir on the back layer.
  • a block polymer made of polystyrene and polyisoprene e.g. Cariflex TR-1 107, Shell
  • the reservoir coat obtained under B is laminated onto the skin gash line A and then the more siliconized film mentioned under B is removed. Now the primer coat C is applied in the same way and a 12 ⁇ m thick polyester film is laminated on after removing the more siliconized film mentioned under C.
  • the finished plasters are punched out of the total laminate.
  • a heat-sealable laminate made of a flexible polyester film and a film made of a polyethylene / vinyl acetate copolymer is sealed against a 50 ⁇ m thick membrane made of a polyethylene / vinyl acetate copolymer with a vinyl acetate content of 19% in accordance with the dimensions and shapes of the later plasters Kind of flat bag arises.
  • the sealing seam should have a width of 4 mm.
  • a liquid preparation made from a silicone oil with 10% acetylsalicylic acid and 0.05% acetic anhydride.
  • the membrane side of the pouch is then laminated onto a silicone-based skin adhesive layer located on a suitable, abhesively finished film. This film is identical to the removable protective layer.
  • the finished systems are punched out so that a bag with a 3 mm thick sealing edge remains.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un système d'administration transdermique pour la thérapie antithrombotique et la prophylaxie contre le cancer, contenant, comme principe actif, de l'acide acétylsalicylique et/ou des sels de cet acide pharmaceutiquement acceptables.
EP94900819A 1992-12-07 1993-11-18 Systeme d'administration transdermique contenant de l'acide acetylsalicylique pour la therapie antithrombotique et la prophylaxie contre le cancer Ceased EP0671916A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4241128 1992-12-07
DE4241128A DE4241128C2 (de) 1991-12-20 1992-12-07 Verwendung eines transdermalen Verabreichungssystems, das als Wirkstoff Acetylsalicylsäure und/oder pharmazeutisch akzeptable Salze davon enthält
PCT/EP1993/003231 WO1994013302A1 (fr) 1991-12-20 1993-11-18 Systeme d'administration transdermique contenant de l'acide acetylsalicylique pour la therapie antithrombotique et la prophylaxie contre le cancer

Publications (1)

Publication Number Publication Date
EP0671916A1 true EP0671916A1 (fr) 1995-09-20

Family

ID=6474576

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94900819A Ceased EP0671916A1 (fr) 1992-12-07 1993-11-18 Systeme d'administration transdermique contenant de l'acide acetylsalicylique pour la therapie antithrombotique et la prophylaxie contre le cancer

Country Status (14)

Country Link
EP (1) EP0671916A1 (fr)
JP (1) JP3799502B2 (fr)
AU (1) AU694410B2 (fr)
CA (1) CA2150033A1 (fr)
CZ (1) CZ149495A3 (fr)
FI (1) FI120719B (fr)
HR (1) HRP931474A2 (fr)
HU (1) HUT75680A (fr)
IL (1) IL107867A (fr)
NO (1) NO952234L (fr)
NZ (1) NZ258129A (fr)
PL (1) PL174770B1 (fr)
SK (1) SK75495A3 (fr)
ZA (1) ZA939126B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2344062T5 (es) * 2003-01-23 2013-04-26 Shire Biopharmaceuticals Holdings Ireland Limited Formulación y procedimientos para el tratamiento de la trombocitopenia
US8658625B2 (en) 2004-02-16 2014-02-25 Teikoku Seiyaku Co., Ltd. External preparation for treating painful skin wound
US8304420B2 (en) 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
US7910597B2 (en) 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
JP6720257B2 (ja) * 2018-09-05 2020-07-08 テックフィールズ インコーポレイテッド 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2496459A1 (fr) * 1980-12-19 1982-06-25 Astier Laboratoires Docteur P Composition pharmaceutique sous forme d'un gel contenant de l'acide acetylsalicylique
IL68965A (en) * 1983-06-13 1987-02-27 Rafa Labor Ltd Topical pharmaceutical preparation comprising acetylsalicylic acid for the treatment of dermatological disorders
HRP921157A2 (en) * 1991-12-20 1994-10-31 Lohmann Therapie Syst Lts Transdermal system of applying acetilsalicilyc acid in antithrombosys therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9413302A1 *

Also Published As

Publication number Publication date
NO952234D0 (no) 1995-06-06
AU694410B2 (en) 1998-07-23
CZ149495A3 (en) 1996-03-13
AU5563294A (en) 1994-07-04
NZ258129A (en) 1999-10-28
FI952805A0 (fi) 1995-06-07
IL107867A (en) 1998-08-16
SK75495A3 (en) 1996-05-08
JPH08504198A (ja) 1996-05-07
PL174770B1 (pl) 1998-09-30
HUT75680A (en) 1997-05-28
CA2150033A1 (fr) 1994-06-23
JP3799502B2 (ja) 2006-07-19
HRP931474A2 (en) 1994-12-31
NO952234L (no) 1995-06-06
PL309285A1 (en) 1995-10-02
IL107867A0 (en) 1994-04-12
FI120719B (fi) 2010-02-15
ZA939126B (en) 1994-08-05
FI952805A (fi) 1995-06-07
HU9501641D0 (en) 1995-08-28

Similar Documents

Publication Publication Date Title
EP0617623B1 (fr) Systeme d'administration transdermique contenant de l'acide acetylsalicylique pour la therapie antithrombotique
EP2094249B1 (fr) Système thérapeutique transdermique destiné à l'administration de l'agent actif buprénorphine
DE3910543C2 (fr)
DE4241874C2 (de) Medizinisches Pflaster für die perkutane Verabreichung des Wirkstoffs Ketoprofen
WO1990004397A1 (fr) Preparation pour application transcutanee renfermant du gestodene
WO1994004157A1 (fr) Agent d'application transdermique contenant du 3-ceto-desogestrel
WO2002002111A1 (fr) Systeme therapeutique dermique contenant des antiphlogistiques non steroidiens a inhibition selective de la cox-2
DE4305881C1 (de) Transdermales therapeutisches System mit Wirkstoffen, welche Stichoxid-Quellen darstellen, Verfahren zu seiner Herstellung sowie seine Verwendung
DE60101206T2 (de) Transdermale verabreichung von lasofoxifen
WO2002005809A1 (fr) Systeme d'application dermique pour l'acide aminolevulinique
EP0671916A1 (fr) Systeme d'administration transdermique contenant de l'acide acetylsalicylique pour la therapie antithrombotique et la prophylaxie contre le cancer
DE10004790A1 (de) Transdermales therapeutisches System zur Verabreichung von Zaleplon
WO1994013302A1 (fr) Systeme d'administration transdermique contenant de l'acide acetylsalicylique pour la therapie antithrombotique et la prophylaxie contre le cancer
EP0668074B1 (fr) Système thérapeutique transdermique
DE19850517A1 (de) Vorrichtung für eine transdermale und phonophoretische Kombinationsbehandlung und ihre Verwendung in einem Verfahren zur medizinischen Anwendung
AT504040B1 (de) Diclofenac-hältige zubereitung zur behandlung von verbrennungen
WO1991009634A1 (fr) Composition a application transcutanee contenant du rolipram
WO2001041771A2 (fr) Systeme transdermique contenant de l'acide acetylsalicylique pour le traitement de la migraine
WO1994005295A1 (fr) Systeme therapeutique percutane contenant du pentylenetetrazol comme principe actif
DE10025971A1 (de) Transdermales therapeutisches System mit verminderter Tendenz zur Wirkstoffkristallisation
DE10025328A1 (de) Acetylsalicylsäure enthaltendes superfizielles therapeutisches System zur Behandlung von Hautschmerzen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950603

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19951208

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KISSEL, THOMAS

Inventor name: BECHER, FRANK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19970621